Company / R&D Expense
AETHLON MEDICAL INC R&D Expense History
FY2014-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$2.2M
FY2024
5-year range
$896.0K / $2.7M
FY2020-FY2024
Trend
-12.2%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has fluctuated over the past 10 years, ranging from $673,000 in FY2016 to $3M in FY2022.
Based on SEC 10-K filings.
$2M in FY2024 with a 10-year CAGR of +4.4%.
Declined from $3M to $2M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +33.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- +4.4%
Key checks
Key Insights
- 3-year CAGR of +33.6%, indicating consistent growth.
- In FY2024, r&d expense decreased 12.2% year-over-year.
- Peak r&d expense was recorded in FY2022.
- Lowest r&d expense in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.04 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $2.2M | -12.2% |
| FY2023 | $2.5M | -8.2% |
| FY2022 | $2.7M | +196.1% |
| FY2021 | $927.0K | +3.5% |
| FY2020 | $896.0K | +0.0% |
| FY2018 | $896.0K | +14.6% |
| FY2017 | $782.0K | +16.2% |
| FY2016 | $673.0K | -55.4% |
| FY2015 | $1.5M | +4.8% |
| FY2014 | $1.4M | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026